Eric Eldering

Our group investigates apoptosis regulation in normal and pathological immune cells. We collaborate closely with the Department of Hematology (professors Arnon Kater and Marie José Kersten on hemato-oncology mainly focused on Chronic Lymphocytic Leukemia (CLL).
Key aspects: novel treatment strategies that circumvent microenvironmental- and p53-induced chemoresistance; BH3 mimetics, kinase inhibitors and anti-CD20 antibodies; biochemical and genetic analyses of (novel) cancer mutations such as TP53, ATM, SF3B1 and Notch1; B cell activation, effector and memory T cell formation, and cancer-induced changes in cellular metabolism.


Department of Experimental Immunology, AMC Amsterdam, Amsterdam, The Netherlands


Slinger E, Thijssen R, Kater AP, Eldering E. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia. 2017.

Peperzak V, Slinger E, Ter Burg J, Eldering E. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Cell Death Differ. 2017.

Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodriguez MS, Michot JM, Hallek M, Eichhorst B, et al. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood. 2016.

Wensveen FM, Slinger E, van Attekum MH, Brink R, Eldering E. Antigen-affinity controls pre-germinal centser B cell selection by promoting Mcl-1 induction through BAFF receptor signaling. Sci Rep. 2016.

Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, Kater AP, Eldering E. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015.


Margot Jak: Microenvironment and anti-CD20 based therapies in CLL. Awarded: 2012

Jaqueline Tromp: The microenvireonment and treatment resistance in CLL. Awarded: 2012

Doreen te Raa: Beyond the horizon; Molecular charactersitoics and prognosis in CLL. Awarded: 2015

Rachel Thijssen: The interplay between micronenviroenmental signaling and novel targeted drugs in CLL. Awarded: 2016

Martijn van Attekum: Formation of a tumor supportive microenvironment in CLL; addressing the reciprocal interacitons in the CLL-T cell-macrophage triad. Awarded: 2017

Current PhD projects

Alexander Leeksma: Nieuwe mutaties in CLL

Fabio Brocco: Fighting resistance in CLL

Raquel Delgado: Regulation of survival and cell death pathways in CLL

Marco Haselager: Survival signaling in CLL

Chen Zhenghao: Metabolic reprogramming in CLL